Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 400-910-1 | CAS number: 119822-74-1
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: oral
Administrative data
- Endpoint:
- short-term repeated dose toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 20 July 1987 to 06 April 1988
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 988
- Report date:
- 1988
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 407 (Repeated Dose 28-Day Oral Toxicity Study in Rodents)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.7 (Repeated Dose (28 Days) Toxicity (Oral))
- GLP compliance:
- yes (incl. QA statement)
- Limit test:
- no
Test material
- Test material form:
- solid: particulate/powder
- Specific details on test material used for the study:
- Identification: FAT 20 306/B
Description: powder
Batch number: HT 2025/50
Purity: 96 %
Stability of test article: stable; expiration: year 2014
Stability of test article dilution: stable for at least 2 hours
Instructions for test article storage: room temperature
Test animals
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
-Strain: Wistar rat, KFM-Han., outbred, SPF quality
- Source: Kleintierfarm Madoerin AG CH 4414 Fuellinsdorf/Switzerland
- Age at pretest: 7 - 8 weeks
- Weight at pretest: males: 153 - 174 g; females: 150 - 184 g
- Housing: Individually in Makrolon type-3 cages with standard softwood bedding
- Diet: Pelleted standard Kliba no. 343, Batch 73/87 and 77/87 rat maintenance diet ('Kliba', Klingentalmuehle AG, 4303 Kaiseraugst, Switzerland) ad libitum
- Water: Community tap water from Itingen was available ad libitum.
- Acclimation period: Seven days under laboratory conditions, after veterinary examination
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22 ±3
- Humidity (%): 40 - 70
- Air changes (per hr): 10 - 15
- Photoperiod (hrs dark / hrs light): 12 hours artificial fluorescent light/12 hours dark, music/light period
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- CMC (carboxymethyl cellulose)
- Remarks:
- 4% (CMC)
- Details on oral exposure:
- TEST ARTICLE PREPARATION: The test article was weighed into a glass beaker on a tared Mettler PK 300 balance and the vehicle, carboxymethyl cellulose 4 % (CMC) in distilled water, was added. The mixture was prepared dally prior to administration using a homogenizer and kept stable during application with a magnetic stirrer.
Method: Oral by gavage, once daily. The control animals received the vehicle without the test article.
Frequency: Once daily, 7 days per week
Dose volume: 10 ml/kg body weight - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Concentration, homogeneity and stability of the test article/vehicle mixture was determined during pretest. Intercurrent sampling for analyses was additionally performed during week 3 of test. Analyses were performed in the RCC Analytical Chemistry Laboratories, according to a method supplied by the sponsor.
- Duration of treatment / exposure:
- 28 days
- Frequency of treatment:
- Once daily, 7 days per week
Doses / concentrationsopen allclose all
- Dose / conc.:
- 0 mg/kg bw/day (actual dose received)
- Remarks:
- Control
- Dose / conc.:
- 50 mg/kg bw/day (actual dose received)
- Remarks:
- Low dose
- Dose / conc.:
- 200 mg/kg bw/day (actual dose received)
- Remarks:
- Middle dose
- Dose / conc.:
- 1 000 mg/kg bw/day (actual dose received)
- Remarks:
- High dose
- No. of animals per sex per dose:
- 5/sex for test concentrations of 50 mg/kg and 200 mg/kg
10/sex for test concentrations of 0 mg/kg and 1000 mg/kg - Control animals:
- yes, concurrent vehicle
- Details on study design:
- TEST ARTICLE PREPARATION
The test article was weighed into a glass beaker on a tared Mettler PK 300 balance and the vehicle, carboxymethyl cellulose 4 % (CMC) in distilled water, was added. The mixture was prepared dally prior to administration using a homogenizer and kept stable during application with a magnetic stirrer.
TEST METHOD
In this subacute toxicity study, test article was administered daily by gavage to SPF-bred Wistar rats of both sexes at dose levels of 0, 50, 200 and 1000 mg/kg body weight/day for a period of 28 days. After termination of the treatment period animals were observed for a further 14 -day treatment-free recovery period. - Positive control:
- no data
Examinations
- Observations and examinations performed and frequency:
- VIABILITY / MORTALITY: Observations for mortality were recorded once daily.
CLINICAL SIGNS: Signs of toxicity were assessed once daily. Descriptions of all abnormalities were recorded, and the subsequent progress was monitored.
FOOD CONSUMPTION: The food consumption was recorded once during the acclimation period and weekly thereafter using an on-line electronic recording system consisting of a Mettler PK 4800 balance connected to the RCC computer.
BODY WEIGHTS: The body weight of each animal was recorded weekly during the acclimation and treatment period using an on-line electronic recording system consisting of a Mettler PK 4800 balance connected to the RCC computer.
OPHTHALMOSCOPIC EXAMINATIONS: at 4 weeks and at 6 weeks. Ophthalmoscopic examinations were performed on all animals. A description of any abnormality was recorded. Examinations were performed at termination of treatment and recovery period. - Sacrifice and pathology:
- ORGAN WEIGHTS: The following organ weights were taken from all animals necropsied after 4 and 6 weeks respectively: Adrenals, Kidneys, Liver, Testes.
NECROPSY: after 4 weeks and after 6 weeks. All animals were necropsied, and descriptions of all macroscopic abnormalities were recorded. Necropsies were performed by experienced prosectors supervised by a pathologist. All animals surviving to the end of the observation period and all moribund animals were anesthetized by intraperitoneal injection of sodium pentobarbitone and killed by exsanguination.
HISTOTECHNOLOGY: All organ and tissue samples, as defined under Histopathology (following) were processed, embedded and cut at a thickness of 2 - 4 micrometers and stained with hematoxylin and eosin.
HISTOPATHOLOGY: Tissue samples of Adrenals, Heart, Kidneys, Liver, Spleen and Gross lesions collected at the end of the assigned study periods from the animals of the control and high-dose groups were examined by a pathologist. - Other examinations:
- Clinical Laboratory Investigations:
Blood samples for hematology and clinical biochemistry were collected from all animals under light ether anesthesia
Blood and urine sampling: at 4 weeks and at 6 weeks - Statistics:
- The following statistical methods were used to analyze the body weights, food consumption, organ weights and clinical laboratory data:
Univariate one-way analysis of variance was used to assess the significance of intergroup differences.
If the variables could be assumed to follow a normal distribution, the Dunnett test (many to one t-test) based on a pooled variance estimate was applied for the comparison between the treated groups and the control groups.
The Steel-test (many-one rank test) was applied when the data could not be assumed to follow a normal distribution.
For the overall spontaneous mortality data, the Fisher's exact test for 2x2 tables was applied.
Group means were calculated for continuous data and medians were calculated for discrete data (scores) 1n the summary tables.
Results and discussion
Results of examinations
- Clinical signs:
- no effects observed
- Description (incidence and severity):
- Group 2 - 5 0 mg/kg:
One male animal (no. 12) showed slight sedation (days 17-18) and slight ruffled fur (days 17-29) and one female animal (no. 43) showed slight ruffled fur (days 17-29) during the treatment period. As shown above the animals had recovered from clinical signs at day 2 of the recovery period.
Group 3 - 200 mg/kg:
Four males (nos. 16, 18, 19 and 20) and two females (nos. 47 and 49) showed slight sedation, dyspnea, ruffled fur and alopecia at different days during weeks 2 to 4 and at day 29 (week 5, first day of recovery). The symptoms described were not all observed in the same animals as well as not all during the same observation period.
Group 4 - 1000 mg/kg:
Nine males (nos. 21-29) and ten females (nos. 51-60) showed slight respectively slight to moderate sedation, dyspnea, rales, ruffled fur, hunched posture, loss of weight and stiff gait. These symptoms were observed at different days during weeks 2 to 4. The intensity and duration varied among the animals. The animals which were kept for an additional recovery period of 14 days were not 1n all cases free of symptoms at termination of recovery. Nevertheless, most symptoms had recovered between days 2 to 10 of the treatment-free period. - Mortality:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- no effects observed
- Food efficiency:
- not specified
- Water consumption and compound intake (if drinking water study):
- not specified
- Ophthalmological findings:
- no effects observed
- Description (incidence and severity):
- No treatment-related findings were noted at termination of treatment and/or recovery.
- Haematological findings:
- no effects observed
- Clinical biochemistry findings:
- no effects observed
- Urinalysis findings:
- no effects observed
- Behaviour (functional findings):
- not specified
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Description (incidence and severity):
- The absolute kidney weights of the male rats of group 3 as well as kidney to body weight ratios of the male rats of group 4 were increased at termination of treatment period.
In addition, the liver weight ratios of the female rats of group 4 were reduced at termination of the recovery period.
These statistical differences were considered to be incidental and of no toxicological or biological relevance. - Gross pathological findings:
- no effects observed
- Histopathological findings: non-neoplastic:
- no effects observed
Effect levels
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 1 000 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: Based on study findings
Target system / organ toxicity
- Critical effects observed:
- no
Applicant's summary and conclusion
- Conclusions:
- The "no observed adverse effect level" (NOAEL) and "no-toxic-effect-level" (NOEL) of FAT 20306/B is 1000 and 50 mg/kg bw respectively for male and females rats when administered by oral gavage.
- Executive summary:
In a GLP-compliant subacute 28-day toxicity study, FAT 20306/B was administered daily by gavage to Wistar rats according OECD guideline 407. The study was comprised of four groups (0, 50, 200 and 1000 mg/kg body weight) with a 14-day recovery period. Starting with day 17 of treatment one male and one female rat of the low-dose group showed slight sedation and ruffled fur. In addition, four males and two females of the mid-dose as well as nine males and ten females of the high-dose group showed dyspnea, ruffled fur, alopecia, sedation, rales, hunched posture, stiff gait and loss of weight. These symptoms were classified as slight to moderate. They were different in duration and intensity among the animals. A clear dose-relation was observed. However, 2 days following exposure these symptoms disappeared (reversible).
No treatment-related effects were noted on all the parameters observed during the study such as mortality, food consumption, body weight, clinical signs, ophthalmoscopic examination, haematology, clinical chemistry, urine analysis, organ weight, gross and histo pathology.
Based upon the results the "no observed adverse effect level" (NOAEL) and "no-toxic-effect-level" (NOEL) of FAT 20306/B is 1000 and 50 mg/kg bw respectively for male and females rats when administered by oral gavage.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.